

1 **Title: Quantifying the Spectrum of Early Motor and Language Milestones in Sex**
2 **Chromosome Trisomy**
3

4 Talia Thompson, PhD^{1,2,3}, Samantha Bothwell, M.S.^{1,3}, Jennifer Janusz, PsyD^{1,2}, Rebecca
5 Wilson, PsyD^{1,2}, Susan Howell, MBA, MS, CGC^{1,2}, Shanlee Davis, MD, PhD^{1,2}, Karli Swenson,
6 PhD, MPH^{1,2}, Sydney Martin, MS, OTR¹, Karen Kowal, PA⁴, Chijioke Ikomi, MD⁴, Maria
7 Despradel¹, Judith Ross, MD⁴, Nicole Tartaglia, MD^{1,2}
8

9 **Affiliations:**

10 ¹eXtraOrdinary Kids Clinic & Research Program, Children's Hospital Colorado, Aurora, CO

11 ²Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO

12 ³Child Health Biostatistics Core, University of Colorado School of Medicine, Aurora, Colorado.

13 ⁴Nemours Children's Hospital, Delaware
14

15 **ORCID:**

16 Talia Thompson: 0000-0001-6512-9743

17 Samantha Bothwell: 0000-0002-1616-8137

18 Jennifer Janusz: 0000-0002-6877-0947

19 Susan Howell: 0000-0001-7115-2165

20 Shanlee Davis: 0000-0002-0304-9550

21 Karli Swenson: 0000-0003-0513-7308

22 Sydney Martin: 0009-0006-5671-0142

23 Maria Despradel: 0009-0005-7413-1649

24 Judith Ross: 0000-0002-8613-2498

25 Nicole Tartaglia: 0000-0002-8529-6722

26 Chijioke Ikomi: 0000-0002-0630-2355
27

28 **Disclosures:**

29 The authors have no disclosures to report.
30

31 **Funding:**

32 This study was funded by the eXtraordinary Babies Study: Natural History of Health and
33 Neurodevelopment in Infants and Young Children with Sex Chromosome Trisomy (NIH NICHD
34 R01HD091251, 3R01HD091251-05S1)
35

36 **Corresponding Author:**

37 Nicole Tartaglia, MD

38 13123 East 16th Ave, B140

39 Aurora, CO 80045

40 Nicole.Tartaglia@ChildrensColorado.org
41

42 **Author contributions:**

43 - Conceptualization - Talia Thompson, Nicole Tartaglia

44 - Statistical analysis - Samantha Bothwell

45 - Data collection - Jennifer Janusz, Rebecca Wilson, Susan Howell, Nicole Tartaglia,
46 Shanlee Davis, Judy Ross, Karen Kowal, Chijioke Ikomi, Talia Thompson

- 47 - Critical reviewing of the manuscript - Jennifer Janusz, Rebecca Wilson, Susan Howell,
48 Shanlee Davis, Karli Swenson, Sydney Martin, Judith Ross, Maria Despradel
49 - Data cleaning - Maria Despradel

50

51 **Abbreviations:**

- 52 SCT - Sex Chromosome Trisomy
53 CDC - Centers for Disease Control
54 AAP - American Academy of Pediatrics
55 DS - Down syndrome
56 FXS - Fragile X syndrome
57 CNS - Central Nervous System
58 WHO - World Health Organization
59 PRP - Primitive Reflex Profile
60 SDoH - Social Determinants of Health
61 EI – Early Intervention

62

63 **Abstract:**

64

65 **Background and objectives:** Sex chromosome trisomy (SCT) is a common chromosomal
66 abnormality associated with increased risks for early developmental delays and
67 neurodevelopmental disorders later in childhood. Our objective was to quantify the spectrum of
68 early developmental milestones in SCT. We hypothesized later milestone achievement in SCT
69 than the general population.

70

71 **Methods:** Data were collected as part of the eXtraordinary Babies Study, a prospective natural
72 history of developmental and health trajectories in a prenatally identified sample of infants with
73 SCT. Parent reported, clinician-validated, early motor and language milestones were collected at
74 2, 6, 12, 18, 24, and 36-months. Age distributions of milestone achievement were compared with
75 normative data.

76

77 **Results:** In all SCT conditions, compared with normative data, there was increased variability
78 and a later median age of skill development across multiple gross motor and expressive language
79 milestones. Results also show a significant amount of overlap with the general pediatric
80 population, suggesting that for many children with prenatally identified SCT, early milestones
81 present within, or close to, the expected timeline.

82

83 **Conclusions:** As increasing numbers of infants with prenatal SCT diagnoses present at pediatric
84 practices, we provide an evidence-based schedule of milestone achievement in SCT as a tool for
85 pediatricians and families. Detailed data on SCT milestones can support clinical interpretation of
86 milestone achievement. Increased variability and later median age of milestone acquisition in
87 SCT compared to norms support consideration of all infants with SCT as high risk.

88

89

90

Background

91
92 Sex chromosome trisomy (SCT) (XXY/Klinefelter syndrome, XYY/Jacob syndrome,
93 XXX/Trisomy X) is a common chromosomal abnormality, occurring in 1 of every 500 live
94 births.¹ Prior SCT research, limited by ascertainment bias and small sample sizes, has provided
95 broad descriptions of early development, including profiles of increased risk for delays in gross
96 motor and communication^{2,3} and high rates of early intervention.⁴ Recent advances in
97 noninvasive prenatal screening⁵ have led to increasing rates of prenatally identified SCT and
98 subsequently a growing population of infants with a confirmed SCT diagnosis early in life. As
99 the literature lacks concrete information on the timing of typical milestone achievement in SCT,
100 parents and providers lack clear guidance on what to expect during a child's early years.
101
102 Close surveillance of key developmental milestones is a critical part of pediatric care, supporting
103 the promotion of healthy development and the early detection of potential developmental
104 delays.⁶ However, common surveillance methods (e.g., CDC milestones⁷ checklists) may have
105 less utility for children with genetic conditions and those at-risk for delays such as infants born
106 prematurely. Research has shown that the timing of milestone acquisition differs from the
107 general population in children with Down syndrome (DS),⁸ fragile X (FXS),⁹ and preterm and
108 very low birthrate infants.⁹⁻¹¹ If this is the case for SCT as well, early developmental care should
109 go beyond surveillance and general screening to include periodic direct developmental
110 assessment. Further, a clear understanding of when children with SCT acquire key
111 developmental milestones is critical for setting reasonable expectations, alerting families to
112 potential concerns, and guiding providers in their referrals for early intervention. This is
113 especially important with the increased frequency of prenatal SCT diagnoses, as pediatricians

114 will be responsible for developmental care in a higher number of infants with SCT presenting to
115 their practices. Therefore, the primary purpose of this study is to fill this gap in the SCT literature
116 with a current, evidence-informed schedule of key early gross motor and language milestone
117 achievement for each of the SCT conditions. These findings will support a more personalized
118 approach to monitoring and care in SCT. Comparisons with previously published normative data
119 to the three SCT conditions will provide critical context and a richer understanding of the SCT
120 phenotypes, and guide recommendations for early developmental care.

121 **Methods**

122 Data were collected as part of the IRB-approved eXtraordinary Babies Natural History Study,
123 which leverages recent advances in genetic testing with a prospective investigation of the
124 developmental and health trajectories in a prenatally identified sample of infants with SCT
125 (ClinicalTrials.gov NCT03396562; COMIRB 17-0118; Nemours IRB# 1151006). Inclusion
126 criteria are prenatal identification of SCT (by cfDNA, chorionic villi sampling, and/or
127 amniocentesis) with diagnostic confirmatory karyotype (chorionic villi sampling, amniocentesis,
128 or postnatal), English or Spanish speaking, and child age of 6 weeks to 12 months upon
129 enrollment. Children are excluded from participation if there is a previous diagnosis of a
130 different genetic or metabolic disorder with neurodevelopmental or endocrine involvement,
131 prematurity less than 34 weeks gestational age, a complex congenital malformation not
132 previously associated with SCT, history of significant neonatal complications (i.e.,
133 intraventricular hemorrhage, meningitis, hypoxic-ischemic encephalopathy), or known central
134 nervous system (CNS) malformation identified by neuroimaging. Study visits are conducted
135 regularly at ages 2, 6, 12, 18, 24 months, and then yearly at two sites (Colorado and Delaware)
136 with a combination of in-person and telehealth visits. Visits include comprehensive health and

137 developmental history, current interventions, physical examination, and a battery of
138 developmental assessments and parent questionnaires. Participants with gestational age <37
139 weeks at birth were excluded from this analysis. Tartaglia et al., (2020) provides additional
140 details on the eXtraordinary Babies natural history study protocol.

141

142 *Developmental Milestone Measurement*

143 Data on the timing of milestones were collected at every study visit as part of a parent completed
144 health and development questionnaire asking parents to report the age (in months) their child
145 achieved key developmental milestones, including eight gross motor skills (rolling front to back,
146 rolling back to front, sitting independently, crawling, cruising, walking, running, jumping) and
147 four expressive communication milestones (cooing, babbling, single words, 2-word phrases).
148 These milestones were chosen because they can be easily observed by parents within a natural
149 setting and delays may predict other areas of known concern in older children with SCT. During
150 the study visit, a physician then reviewed the parent questionnaire responses by interview to
151 confirm ages and parent understanding of the milestone. If there were discrepancies between
152 parent reported skill and the milestone achieved (for example the parent reported the infant was
153 “sitting independently” but physician confirmed the infant was only sitting in a propped
154 position), the physician would adjust the data on the physician data form. The physician data
155 form was used for data analysis.

156

157 *Normative data*

158 Each of the twelve developmental milestones collected for the study sample were compared with
159 existing published norms. We included normative data from studies with published values for the

160 25th, 50th, 75th, and 90th percentiles for the milestones of interest from the Denver II Scales,¹² the
161 World Health Organization (WHO) Motor Development Study,¹³ and the Primitive Reflex Profile
162 (PRP).¹⁴ As normative data were not available from a single source for all twelve milestones, we
163 used the Denver II whenever possible (sitting, walking, running, jumping, cooing, babbling,
164 single words, 2-word phrases). For milestones that were not included on the Denver II, we used
165 data from the WHO (crawling and cruising) and the PRP (rolling front to back, rolling back to
166 front). As the PRP normative dataset only provided means and standard deviations, percentiles
167 were estimated theoretically under the assumption of a normal distribution.

168 *Analysis*

169 All analyses were performed in R, version 4.4.0. Descriptive summaries by SCT are presented as
170 median [interquartile range] and N (%). Demographic differences between SCTs were tested
171 using Kruskal-Wallis tests for continuous variables and Fisher's-Exact tests for categorical
172 variables. For each milestone, achieved ages earlier than the normative 2.5th percentile were
173 removed as early outliers. Normative and SCT milestone ages are visualized from their 25th –
174 50th, 50th – 75th, and 75th – 90th percentiles. Differences in milestones were analyzed using
175 simulated data based on the normative percentiles, under the assumption of a non-normal
176 distribution, and were tested with Wilcoxon Rank-Sum tests. Differences in milestones were also
177 analyzed between children who had a history of early intervention (EI) therapies and those who
178 did not. Exploring whether there was an overall relationship of milestone achievement with
179 receiving EI therapy was important to ensure therapies were not significantly impacting the
180 distribution of milestones achievement.

181

182

Results

183 Participants include 298 young children with prenatally identified SCT, including 174 with XXY,
184 50 with XYY, and 74 with XXX. All included children had at least one milestone age reported.
185 Table 1 shows sample characteristics. At the time of analysis, the median age of patients included
186 was 4.5 years with the youngest group being XYY children, with a median age of 2.6. The
187 majority of the cohort was white (81.9%) and non-Hispanic/Latinx (83.9%). Included children
188 had participated in the eXtraordinary Babies study for a median of 3 years, with XXY children
189 having participated the longest (median: 3.5 [IQR: 2.7, 3.8] years) and XYY children having
190 participated for the shortest period of time (median: 1.2 [IQR: 0.4, 3.1] years).

191

192 *Timing of Milestone Achievement in SCT Compared with Normative Datasets.*

193 Figure 1 depicts the age (in months) of milestone achievement for each SCT compared with
194 reference norms. Age distributions are characterized by plotting the values for the 25th, 50th, 75th,
195 and 90th percentiles of each milestone and comparing to normative data. Results indicate that the
196 distributions for all twelve milestones differ (later median milestone achievement; $p < 0.05$) from
197 the normative dataset in at least one SCT group per milestone.

198

199 *Group Differences.*

200 Table 2 shows statistical results for group differences in age of milestone achievement between
201 the SCT conditions. Results show statistically significant group differences in cooing ($p = 0.005$);
202 boys with XXY achieved cooing earlier than both girls with XXX ($p = 0.016$) and boys with
203 XYY ($p = 0.006$). Overall group differences exist for crawling ($p = 0.050$) and cruising ($p = 0.012$).
204 Boys with XXY achieved crawling ($p = 0.017$) and cruising ($p = 0.006$) at a significantly younger

205 age than girls with XXX. All other milestone data were statistically similar across trisomy
206 conditions.

207

208 *Comparisons with CDC Milestones*

209 Table 3 shows the percent of children by SCT condition who did not achieve milestones by the
210 age listed on the CDC milestones checklists (CDC milestones purport to represent the specific
211 health supervision visit age when $\geq 75\%$ or more of children are expected to demonstrate the
212 skill).

213

214 *Consideration of Early Intervention Therapies*

215 Of the 298 children included, 187 (63.8%) had received EI therapy, started either proactively due
216 to risk for delays or in response to developmental concerns in one or more developmental
217 domains. There were no differences in therapy rates between the SCT conditions. Within our
218 cohort, children with history of EI achieved milestones significantly later than children who had
219 not ($p < 0.001$ for all milestones). This is likely because those with identified delays were more
220 likely to be referred for developmental therapies.

221

222 **Discussion**

223 This study represents the first report on developmental milestone achievement in prenatally
224 identified SCT and provides a novel milestone chart that can help parents and professionals
225 better quantify and visualize what “increased risk for developmental delay” means in SCT
226 conditions. These cohorts were not referred for any concerns and thus were as close to
227 “population based” as possible. In all SCT conditions, there was a later median age of skill

228 development across multiple gross motor and expressive language milestones than reported in
229 normative datasets. This includes both early milestones such as cooing and rolling, and later
230 milestones including 2-word phrases, walking, and running. Furthermore, there was more
231 variability in the age range for milestone achievement in our sample compared with reference
232 norms, with the range of acquisition for all milestones extending later in life for children with
233 SCT. These findings support the need to consider infants with SCT as a group at increased risk
234 for delays and deserving of closer developmental monitoring given that age of early motor and
235 language milestones have been shown to predict longitudinal outcomes across all developmental
236 domains in the general population and clinical samples.¹⁵⁻²⁶

237 These results confirm prior research indicating increased risk for developmental delays in
238 children with SCT,^{4,27,28} consistent with findings in other genetic disorders where milestone
239 acquisition is different than population norms.²⁹ However, unlike other genetic conditions such
240 as DS and FXS,^{30,31} our results also show a significant amount of overlap with the general
241 pediatric population. Figure 1 shows that, for many children with prenatally identified SCT, early
242 milestones present within, or close to, the expected timeline. While this is reassuring, there are
243 known later risks in SCT for many neurodevelopmental diagnoses including speech-language
244 disorders, learning disabilities, ADHD, executive dysfunction, motor skill deficits, and autism
245 spectrum disorders,³²⁻⁴⁴ which all benefit from earlier diagnosis and evidence-based treatments.
246 Thus, careful attention to development trajectories is warranted as early interventions may help
247 minimize these morbidities.

248 The variability of the phenotype and overlap with the general population often leads to questions
249 of whether different developmental care pathways and extra developmental testing is needed for
250 *all* infants with SCT. This is a valid concern as a relatively high proportion of individuals with

251 SCT conditions have minimal neurodevelopmental differences with positive adult outcomes,⁴⁵⁻⁴⁷
252 and many go undiagnosed from their clinical presentation. Additional recommendations for
253 developmental monitoring and evaluation may increase family stress, negatively impact parent-
254 child relationships, and call unnecessary attention to the genetic differences in their child, as well
255 as increase healthcare utilization and demand on a stressed early intervention system.
256 Prospective longitudinal research is needed to clarify if indeed there are specific early risk
257 factors predictive of poorer outcomes that would warrant stratifying children with SCT into
258 different low versus high-risk developmental care pathways, similar to extensive work done in
259 the congenital heart disease and prematurity populations.^{48,49} These pathways, however, were
260 developed using evidence from hundreds of studies, which do not currently exist in SCT. Thus,
261 until more prospective data is available, consideration of all infants with SCT as high risk is
262 warranted.

263 Table 3 responds to our interest in whether recently published milestones from the CDC⁷ are
264 appropriate for developmental surveillance in infants with SCT. Overall, a relatively small
265 proportion of children in our sample were delayed in milestone achievement according to CDC
266 milestones checklists (Table 3) even though their milestone acquisition was delayed as compared
267 to other metrics (Denver II; WHO). This suggests that relying on the CDC milestone lists for
268 SCT will fail to identify many infants with delayed milestones and is consistent with other
269 published concerns⁵⁰⁻⁵² about low sensitivity of the ages presented in the CDC milestones. It is
270 well recognized that standard developmental screening tools designed for the general population
271 (e.g., ASQ, PEDS)⁵³⁻⁵⁵ have lower sensitivity in high-risk groups, which has led to guidelines for
272 developmental follow-up of high-risk neonates with periodic direct assessment.^{49,56-58} Similarly,

273 our findings of the increased risk in SCT support that periodic direct developmental assessment
274 should be part of SCT treatment guidelines.⁵⁹

275 By offering detailed information on milestone achievement, we provide a valuable tool for
276 clinicians and families to better interpret a child's early development within the context of their
277 SCT condition, rather than only comparing to general population norms. Further, any significant
278 deviations from SCT norms may alert clinicians to potential risks for comorbid health conditions
279 or an additional genetic difference. While pediatric providers can use this tool as a reference to
280 contextualize a child's milestone achievement, it is not intended to delay referrals for
281 developmental evaluations or early intervention support. Parents may appreciate the more
282 nuanced normative data as they track their child's milestones, noting areas where their child's
283 development aligns with children with similar genetic profiles as well as areas of normative
284 differences. Prior research shows parents of children with delayed milestones may have higher
285 levels of perceived stress⁶⁰ or experience guilt that they have done something to cause their
286 child's delays.⁶¹ A clearly defined schedule for the timing of developmental milestones specific
287 to each SCT, when used in conjunction with normative milestones expectations, may be more
288 palatable in supporting early developmental care.

289 Results showing similarities and differences in milestone achievement by karyotype (Table 2)
290 add to the existing literature on genetic disorders by providing more specific data regarding
291 milestone acquisition in each trisomy condition. For most milestones, SCT groups were
292 statistically similar. This aligns with prior research showing similar early developmental and
293 neurocognitive profiles across the SCT conditions.^{44,62-64} However, the XXY group did achieve
294 several milestones earlier, including cooing 1 month earlier than both other groups and crawling
295 and cruising 1 month earlier than those with XXX. While this may be an artifact of a larger and

296 more variable sample size in XXY, it may also reflect differential effects of the extra X
297 chromosome in males.⁶⁵ Ongoing research with larger sample sizes for XYY and XXX will help
298 determine if different SCT conditions have clinically relevant differences in developmental
299 trajectories.

300 These study results also have practical implications for genetic counseling and are responsive to
301 prior research findings showing that parents receiving a prenatal SCT diagnosis desire more
302 accurate and current data on potential neurodevelopmental outcomes specific to each SCT
303 condition. In the context of highly variable phenotypes associated with SCT, genetic counselors
304 strive to provide guidance to parents with a new diagnosis and clarify parental perception of risks
305 for developmental delays.⁶⁶ This foundation establishes how parents understand and respond to
306 their child's development and behavior, especially as related to the genetic diagnosis. By
307 providing a clearer picture of developmental expectations associated with the diagnosis, genetic
308 counselors can more specifically inform parents about what to expect in their child's first few
309 years of life, as well as promote awareness, empowerment, and a proactive approach to early
310 intervention processes to facilitate early developmental care.⁶⁷

311 Despite the insights gained, limitations are important to consider. First, smaller sample sizes for
312 the XXX and XYY karyotypes limit the generalizability compared with the XXY sample.
313 Additionally, there are known limitations in normative data for milestone acquisition, including
314 unclear and inconsistent definitions of milestones,⁶⁸ ambiguity around what constitutes
315 achievement of the milestone (partial vs. complete),⁶⁹ and differences in the raters used to
316 determine milestone achievement for normative datasets (parents vs. clinicians).^{68,70,71} Further,
317 normative datasets rarely account for potential sex differences,^{72,73} racial and sociocultural
318 differences,^{50,74,75} and known variability related to social determinants of health⁶⁹ (SDoH), which

319 further adds a degree of uncertainty to our findings. Our sample was disproportionately white,
320 non-Hispanic with high socioeconomic status, and future studies should aim to include more
321 representative samples. Parental recall bias is another commonly recognized challenge when
322 evaluating parent-reported milestones,^{76,77} however minimized in this study with frequent visits
323 at 2, 6, 12, 18, 24, and 36 months of age with pediatric physicians interviewing and verifying
324 milestone achievements. Importantly, while there are many benefits to an ongoing natural history
325 study, our study design is limited in that at the time of publication, not all participants in the
326 sample had yet achieved all 12 milestones measured and therefore sample sizes were different
327 for each SCT condition at each milestone. Additionally, while we explored the effect of early
328 intervention in our analysis, the act of participating in a natural history study itself may impact
329 developmental course. Families in the study have self-selected to participate in regularly
330 scheduled developmental evaluations with expert SCT clinicians and to monitor developmental
331 milestones in between visits. While a prenatally identified sample of nearly 300 infants with SCT
332 provides a less biased dataset than prior studies, it may still not fully represent the broad
333 spectrum of outcomes in SCT. Future results based on direct assessments through the
334 eXtraordinary Babies study can address these limitations and further refine our understanding of
335 developmental trajectories and risk groups in this population.

336 In conclusion, developmental milestone achievement in SCT conditions is delayed compared to
337 the general population, however only in a subset of infants with SCT. As increasing numbers of
338 infants with prenatal SCT diagnoses present at pediatric practices, we provide an evidence-based
339 schedule of milestone achievement in SCT as a tool for families, pediatricians, genetic
340 counselors, and early intervention teams. Utilization of such a tool can support shared clinical
341 decision-making between parents and providers, promoting timely referrals and identifying

342 patterns inconsistent with SCT. However, given the paucity of prospective research identifying
343 specific risk factors for later negative outcomes, recommended care for SCT conditions should
344 follow practices of other high-risk conditions - with more responsive attention to developmental
345 concerns, recognition that standard surveillance and screening tools have lower sensitivities in
346 high-risk populations, and referrals for periodic direct developmental assessments. While more
347 rigorous research will help identify evidence for timing of direct assessments and highest-risk
348 groups, general publications support assessments at 6-12 months, 18-24 months, and 36 months
349 of age.⁷⁸⁻⁸⁰

350

351 **Table 1.** Cohort Demographics


	Overall (N=298)	XXY (N=174)	XYY (N=50)	XXX (N=74)	P-Value
Age (Years; As of 7/9/2024)					
Median [IQR]	4.5 [2.9, 5.7]	4.9 [3.8, 6.1]	2.6 [1.4, 5.3]	3.5 [2, 5.1]	<0.001*
Years in Study					
Median [IQR]	3 [1.4, 3.8]	3.5 [2.7, 3.8]	1.2 [0.4, 3.1]	2.5 [0.9, 3.5]	<0.001*
Race					
White	244 (81.9%)	138 (79.3%)	41 (82.0%)	65 (87.8%)	0.119
Native Hawaiian or Other Pacific Islander	1 (0.3%)	1 (0.6%)	0 (0%)	0 (0%)	
African American or Black	17 (5.7%)	13 (7.5%)	4 (8.0%)	0 (0%)	
Asian	24 (8.1%)	14 (8.0%)	2 (4.0%)	8 (10.8%)	
Native American or Alaska Native	3 (1.0%)	2 (1.1%)	1 (2.0%)	0 (0%)	
Other	6 (2.0%)	5 (2.9%)	1 (2.0%)	0 (0%)	
Missing	3 (1.0%)	1 (0.6%)	1 (2.0%)	1 (1.4%)	
Ethnicity					
Hispanic/Latinx	45 (15.1%)	28 (16.1%)	6 (12.0%)	11 (14.9%)	0.859
Non-Hispanic/Latinx	250 (83.9%)	145 (83.3%)	43 (86.0%)	62 (83.8%)	
Missing	3 (1.0%)	1 (0.6%)	1 (2.0%)	1 (1.4%)	
Hollingshead Index					
Median [IQR]	54.5 [47.9, 59.5]	54 [47, 59.5]	54.5 [46.1, 59.2]	55.5 [50.5, 59.5]	0.619
Missing	10 (3.4%)	1 (0.6%)	4 (8.0%)	5 (6.8%)	
Annual Family Income*					
\$50,000 or less	17 (5.7%)	12 (6.9%)	3 (6.0%)	2 (2.7%)	0.437
\$50,000 - \$100,000	67 (22.5%)	38 (21.8%)	15 (30.0%)	14 (18.9%)	
\$100,000 - \$250,000	154 (51.7%)	91 (52.3%)	20 (40.0%)	43 (58.1%)	
> \$250,000	54 (18.1%)	30 (17.2%)	11 (22.0%)	13 (17.6%)	
Missing	6 (2.0%)	3 (1.7%)	1 (2.0%)	2 (2.7%)	

Significance level = 0.05. Overall differences tested using Kruskal-Wallis tests for continuous variables and Fisher's Exact/Chi-Squared Tests for categorical variables. *Family income data reported were collected at initial eXtraordinary Babies study visit.

352
353
354

355

356 **Figure 1.** Achievement of Language and Motor milestones in Sex Chromosome Trisomy
 357 compared to the general population



358
 359 *: Trisomy is delayed compared to simulated data based on general population percentiles, under the assumption of a non-normal
 360 distribution. Significance level = 0.05. Differences tested with Wilcoxon Rank-Sum Tests.

361 General Population estimates are based on Denver II for Jumping, Running, Walking, Sitting, 2 Word Phrases, First Words,
 362 Babbling, and Cooing; WHO for Cruising and Crawling; and PRP for Rolling Back to Front and Rolling Front to Back.¹²⁻¹⁴

363

364

365

366 **Table 2.** Age in Months of Milestone Achievement by SCT¹

	XXY (N=174)	XYX (N=50)	XXX (N=74)	Overall Kruskal-Wallis P-Value
Language				
Cooing	<i>N</i> = 165	<i>N</i> = 46	<i>N</i> = 68	
Median [IQR]	2 [1.5, 3]	2.8 [2, 5]	2.5 [2, 4]	0.005* ^{1,2}
Babbling	<i>N</i> = 158	<i>N</i> = 44	<i>N</i> = 61	
Median [IQR]	7 [6, 9]	7.2 [5.9, 9]	7 [5, 9]	0.867
First Words	<i>N</i> = 152	<i>N</i> = 36	<i>N</i> = 55	
Median [IQR]	12 [11, 14]	12 [11, 14]	12 [10.5, 12.5]	0.557
2 Word Phrases	<i>N</i> = 135	<i>N</i> = 23	<i>N</i> = 42	
Median [IQR]	23 [18, 24]	23 [19, 30]	22.5 [18, 24]	0.637
Motor				
Rolling Front to Back	<i>N</i> = 162	<i>N</i> = 44	<i>N</i> = 64	
Median [IQR]	4.5 [3.5, 5.5]	4 [4, 5.6]	4.5 [3.8, 5]	0.891
Rolling Back to Front	<i>N</i> = 162	<i>N</i> = 43	<i>N</i> = 64	
Median [IQR]	5 [4, 6]	5 [4, 7]	5 [4.4, 6]	0.193
Sitting	<i>N</i> = 164	<i>N</i> = 45	<i>N</i> = 60	
Median [IQR]	6 [5.4, 7]	6 [6, 7]	6 [5.5, 7]	0.354
Crawling	<i>N</i> = 162	<i>N</i> = 44	<i>N</i> = 62	
Median [IQR]	8 [7, 9.9]	9 [7.9, 10]	9 [8, 10]	0.050* ²
Cruising	<i>N</i> = 157	<i>N</i> = 41	<i>N</i> = 62	
Median [IQR]	10 [9, 11]	11 [10, 12]	11 [10, 12]	0.012* ²
Walking	<i>N</i> = 156	<i>N</i> = 32	<i>N</i> = 53	
Median [IQR]	13 [12, 15]	14 [12, 15]	14 [12, 16]	0.239
Running	<i>N</i> = 145	<i>N</i> = 27	<i>N</i> = 51	
Median [IQR]	18 [15, 20]	18 [16, 20]	18 [17, 20.5]	0.177
Jumping	<i>N</i> = 131	<i>N</i> = 22	<i>N</i> = 43	
Median [IQR]	23 [20, 30]	26.2 [22, 31.5]	23 [21.5, 29]	0.374

* Significant difference in at least one trisomy; alpha = 0.05

¹ Pairwise test XXY ≠ XYX; Bonferroni adjusted alpha = 0.017

² Pairwise test XXY ≠ XXX; Bonferroni adjusted alpha = 0.017

367
368
369
370
371
372
373

374 **Table 3.** Frequencies of children with SCT delayed in milestones according to ages set by CDC
 375 Milestones checklists.

Milestone	Age	XXY (Total N = 174)	XYY (Total N = 50)	XXX (Total N = 74),
Language				
Cooing	4 months	16/165 (9.7%)	13/46 (28.3%)	11/68 (16.2%)
Babbling	9 months	35/158 (22.12%)	9/44 (20.5%)	13/61 (21.3%)
First Words	15 months	32/1582 (21.1%)	8/36 (22.2%)	10/55 (18.2%)
2 Word Phrases	24 months	33/135 (24.4%)	9/33 (39.1%)	10/42 (23.8%)
Motor				
Rolling Front to Back	6 months	17/162 (10.5%)	7/44 (15.9%)	9/64 (14.1%)
Sitting Independently	9 months	3/164 (1.8%)	1/45 (2.2%)	2/60 (3.3%)
Cruising	12 months	22/157 (14%)	3/41 (7.3%)	13/62 (21%)
Walking	15 months	33/156 (21.2%)	7/32 (21.9%)	19/53 (35.9%)
Running	24 months	12/145 (8.3%)	1/27 (3.7%)	4/51 (7.8%)
Jumping	30 months	22/131 (16.8%)	6/22 (27.3%)	7/43 (16.3%)

376 N (%; p-value): Number (%) of children in each trisomy that achieved the milestone later than the ages listed on CDC milestone
 377 checklists. Total sample sizes differ for each milestone and trisomy.
 378 CDC cut points were not available for rolling back to front and crawling
 379

380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391

392 References:

- 393
- 394 1. JACOBS PA, MELVILLE M, RATCLIFFE S, KEAY AJ, SYME J. A cytogenetic
395 survey of 11,680 newborn infants. *Annals of Human Genetics*. 1974;37(4):359-376.
396 doi:<https://doi.org/10.1111/j.1469-1809.1974.tb01843.x>
- 397 2. Ratcliffe SG. Speech and learning disorders in children with sex chromosome
398 abnormalities. *Dev Med Child Neurol*. Feb 1982;24(1):80-4. doi:10.1111/j.1469-
399 8749.1982.tb13586.x
- 400 3. Salbenblatt JA, Meyers DC, Bender BG, Linden MG, Robinson A. Gross and fine
401 motor development in 47,XXY and 47,XYY males. *Pediatrics*. Aug 1987;80(2):240-4.
- 402 4. Thompson T, Howell S, Davis S, et al. Current survey of early childhood
403 intervention services in infants and young children with sex chromosome aneuploidies.
404 *Am J Med Genet C Semin Med Genet*. Jun 2020;184(2):414-427.
405 doi:10.1002/ajmg.c.31785
- 406 5. Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin,
407 Number 226. *Obstet Gynecol*. Oct 2020;136(4):e48-e69.
408 doi:10.1097/aog.0000000000004084
- 409 6. Lipkin PH, Macias MM. Promoting Optimal Development: Identifying Infants and
410 Young Children With Developmental Disorders Through Developmental Surveillance
411 and Screening. *Pediatrics*. Jan 2020;145(1)doi:10.1542/peds.2019-3449
- 412 7. Zubler JM, Wiggins LD, Macias MM, et al. Evidence-Informed Milestones for
413 Developmental Surveillance Tools. *Pediatrics*. Mar 1
414 2022;149(3)doi:10.1542/peds.2021-052138
- 415 8. Onnivello S, Schworer EK, Daunhauer LA, Fidler DJ. Acquisition of cognitive and
416 communication milestones in infants with Down syndrome. *J Intellect Disabil Res*. Mar
417 2023;67(3):239-253. doi:10.1111/jir.12893
- 418 9. Hinton R, Budimirovic DB, Marschik PB, et al. Parental reports on early language
419 and motor milestones in fragile X syndrome with and without autism spectrum disorders.
420 *Dev Neurorehabil*. 2013;16(1):58-66. doi:10.3109/17518423.2012.704414
- 421 10. Pascal A, Govaert P, Oostra A, Naulaers G, Ortibus E, Van den Broeck C.
422 Neurodevelopmental outcome in very preterm and very-low-birthweight infants born
423 over the past decade: a meta-analytic review. *Dev Med Child Neurol*. Apr
424 2018;60(4):342-355. doi:10.1111/dmcn.13675
- 425 11. Jeng SF, Lau TW, Hsieh WS, et al. Development of walking in preterm and term
426 infants: age of onset, qualitative features and sensitivity to resonance. *Gait Posture*. Feb
427 2008;27(2):340-6. doi:10.1016/j.gaitpost.2007.04.012
- 428 12. Frankenburg WK, Dodds J, Archer P, Shapiro H, Bresnick B. The Denver II: a
429 major revision and restandardization of the Denver Developmental Screening Test.
430 *Pediatrics*. Jan 1992;89(1):91-7.
- 431 13. WHO Motor Development Study: windows of achievement for six gross motor
432 development milestones. *Acta Paediatr Suppl*. Apr 2006;450:86-95. doi:10.1111/j.1651-
433 2227.2006.tb02379.x
- 434 14. Capute AJ, Palmer FB, Shapiro BK, Wachtel RC, Ross A, Accardo PJ. Primitive
435 reflex profile: a quantitation of primitive reflexes in infancy. *Dev Med Child Neurol*. Jun
436 1984;26(3):375-83. doi:10.1111/j.1469-8749.1984.tb04456.x

- 437 15. Flensburg-Madsen T, Sørensen HJ, Revsbech R, Mortensen EL. Early motor
438 developmental milestones and level of neuroticism in young adulthood: a 23-year
439 follow-up study of the Copenhagen Perinatal Cohort. *Psychol Med*. Jun
440 2013;43(6):1293-301. doi:10.1017/s0033291712001997
- 441 16. Bedford R, Pickles A, Lord C. Early gross motor skills predict the subsequent
442 development of language in children with autism spectrum disorder. *Autism Res*. Sep
443 2016;9(9):993-1001. doi:10.1002/aur.1587
- 444 17. Lang S, Bartl-Pokorny KD, Pokorny FB, et al. Canonical Babbling: A Marker for
445 Earlier Identification of Late Detected Developmental Disorders? *Curr Dev Disord Rep*.
446 2019;6(3):111-118. doi:10.1007/s40474-019-00166-w
- 447 18. Ghassabian A, Sundaram R, Bell E, Bello SC, Kus C, Yeung E. Gross Motor
448 Milestones and Subsequent Development. *Pediatrics*. Jul
449 2016;138(1)doi:10.1542/peds.2015-4372
- 450 19. Hua J, Williams GJ, Jin H, et al. Early Motor Milestones in Infancy and Later
451 Motor Impairments: A Population-Based Data Linkage Study. *Front Psychiatry*.
452 2022;13:809181. doi:10.3389/fpsy.2022.809181
- 453 20. Otapowicz D, Sobaniec W, Kułak W, Okurowska-Zawada B. Time of cooing
454 appearance and further development of speech in children with cerebral palsy. *Rocz*
455 *Akad Med Białymst*. 2005;50 Suppl 1:78-81.
- 456 21. Werwach A, Mürbe D, Schaadt G, Männel C. Infants' vocalizations at 6 months
457 predict their productive vocabulary at one year. *Infant Behavior and Development*.
458 2021/08/01/ 2021;64:101588. doi:<https://doi.org/10.1016/j.infbeh.2021.101588>
- 459 22. Oller DK, Seibert JM. Babbling of prelinguistic mentally retarded children. *Am J*
460 *Ment Retard*. Jan 1988;92(4):369-75.
- 461 23. Kover ST, Edmunds SR, Ellis Weismer S. Brief Report: Ages of Language
462 Milestones as Predictors of Developmental Trajectories in Young Children with Autism
463 Spectrum Disorder. *J Autism Dev Disord*. Jul 2016;46(7):2501-7. doi:10.1007/s10803-
464 016-2756-y
- 465 24. Mayo J, Chlebowski C, Fein DA, Eigsti IM. Age of first words predicts cognitive
466 ability and adaptive skills in children with ASD. *J Autism Dev Disord*. Feb
467 2013;43(2):253-64. doi:10.1007/s10803-012-1558-0
- 468 25. Kenworthy L, Wallace G, Powell K, Anselmo C, Martin A, Black D. Early language
469 milestones predict later language, but not autism symptoms in higher functioning
470 children with autism spectrum disorders. *Research in Autism Spectrum Disorders*. 07/01
471 2012;6:1194-1202. doi:10.1016/j.rasd.2012.03.009
- 472 26. Wodka EL, Mathy P, Kalb L. Predictors of phrase and fluent speech in children
473 with autism and severe language delay. *Pediatrics*. Apr 2013;131(4):e1128-34.
474 doi:10.1542/peds.2012-2221
- 475 27. Tartaglia N, Howell S, Davis S, et al. Early neurodevelopmental and medical
476 profile in children with sex chromosome trisomies: Background for the prospective
477 eXtraordinary babies study to identify early risk factors and targets for intervention. *Am*
478 *J Med Genet C Semin Med Genet*. Jun 2020;184(2):428-443. doi:10.1002/ajmg.c.31807
- 479 28. Urbanus E, Swaab H, Tartaglia N, Cordeiro L, van Rijn S. The behavioral profile
480 of children aged 1-5 years with sex chromosome trisomy (47,XXX, 47,XXY, 47,XYY).
481 *Am J Med Genet C Semin Med Genet*. Jun 2020;184(2):444-455.
482 doi:10.1002/ajmg.c.31788

- 483 29. Wickstrom J, Farmer C, Green Snyder L, et al. Patterns of delay in early gross
484 motor and expressive language milestone attainment in probands with genetic
485 conditions versus idiopathic ASD from SFARI registries. *J Child Psychol Psychiatry*. Nov
486 2021;62(11):1297-1307. doi:10.1111/jcpp.13492
- 487 30. Kim HI, Kim SW, Kim J, Jeon HR, Jung DW. Motor and Cognitive Developmental
488 Profiles in Children With Down Syndrome. *Ann Rehabil Med*. Feb 2017;41(1):97-103.
489 doi:10.5535/arm.2017.41.1.97
- 490 31. Mirrett PL, Bailey Jr DB, Roberts JE, Hatton DD. Developmental Screening and
491 Detection of Developmental Delays in Infants and Toddlers with Fragile X Syndrome.
492 *Journal of Developmental and Behavioral Pediatrics*. 2004;25(1):21-27.
493 doi:10.1097/00004703-200402000-00004
- 494 32. Printzlau F, Wolstencroft J, Skuse DH. Cognitive, behavioral, and neural
495 consequences of sex chromosome aneuploidy. *J Neurosci Res*. Jan 2 2017;95(1-
496 2):311-319. doi:10.1002/jnr.23951
- 497 33. Bishop DVM, Brookman-Byrne A, Gratton N, et al. Language phenotypes in
498 children with sex chromosome trisomies. *Wellcome Open Res*. 2018;3:143.
499 doi:10.12688/wellcomeopenres.14904.2
- 500 34. Simpson NH, Addis L, Brandler WM, et al. Increased prevalence of sex
501 chromosome aneuploidies in specific language impairment and dyslexia. *Dev Med Child*
502 *Neurol*. Apr 2014;56(4):346-53. doi:10.1111/dmcn.12294
- 503 35. Boada R, Janusz J, Hutaff-Lee C, Tartaglia N. The cognitive phenotype in
504 Klinefelter syndrome: a review of the literature including genetic and hormonal factors.
505 *Dev Disabil Res Rev*. 2009;15(4):284-94. doi:10.1002/ddrr.83
- 506 36. Bouw N, Swaab H, Tartaglia N, van Rijn S. The impact of sex chromosome
507 trisomies (XXX, XXY, XYY) on early social cognition: Social orienting, joint attention,
508 and theory of mind. *Archives of Clinical Neuropsychology*. 2022;37(1):63-77.
509 doi:10.1093/arclin/acab042
- 510 37. Hong DS, Reiss AL. Cognitive and neurological aspects of sex chromosome
511 aneuploidies. *Lancet Neurol*. Mar 2014;13(3):306-18. doi:10.1016/s1474-
512 4422(13)70302-8
- 513 38. van Rijn S, Swaab H, Aleman A, Kahn RS. Social behavior and autism traits in a
514 sex chromosomal disorder: Klinefelter (47XXY) syndrome. *J Autism Dev Disord*. Oct
515 2008;38(9):1634-41. doi:10.1007/s10803-008-0542-1
- 516 39. Karipidis, II, Hong DS. Specific learning disorders in sex chromosome
517 aneuploidies: Neural circuits of literacy and mathematics. *Am J Med Genet C Semin*
518 *Med Genet*. Jun 2020;184(2):518-530. doi:10.1002/ajmg.c.31801
- 519 40. Thompson T, Davis S, Janusz J, et al. Supporting students with sex chromosome
520 aneuploidies in educational settings: Results of a nationwide survey. *J Sch Psychol*. Aug
521 2022;93:28-40. doi:10.1016/j.jsp.2022.06.002
- 522 41. Martin S, Cordeiro L, Richardson P, Davis S, Tartaglia N. The Association of
523 Motor Skills and Adaptive Functioning in XXY/Klinefelter and XYY Syndromes. *Phys*
524 *Occup Ther Pediatr*. 2019;39(4):446-459. doi:10.1080/01942638.2018.1541040
- 525 42. Tartaglia NR, Ayari N, Hutaff-Lee C, Boada R. Attention-deficit hyperactivity
526 disorder symptoms in children and adolescents with sex chromosome aneuploidy: XXY,
527 XXX, XYY, and XYY. *J Dev Behav Pediatr*. May 2012;33(4):309-18.
528 doi:10.1097/DBP.0b013e31824501c8

- 529 43. Kuiper KC, Swaab H, Tartaglia N, van Buggenhout G, Wouters C, van Rijn S.
530 The developmental impact of sex chromosome trisomies on emerging executive
531 functions in young children: Evidence from neurocognitive tests and daily life skills.
532 *Genes Brain Behav.* Jul 2022;21(6):e12811. doi:10.1111/gbb.12811
- 533 44. van Rijn S, Kuiper K, Bouw N, Urbanus E, Swaab H. Neurocognitive and
534 behavioral development in young children (1-7 years) with sex chromosome trisomy.
535 *Endocr Connect.* May 1 2023;12(5)doi:10.1530/ec-22-0494
- 536 45. Davis SM, Teerlink CC, Lynch JA, et al. An extra X chromosome among adult
537 women in the Million Veteran Program: A more benign perspective of trisomy X. *Am J*
538 *Med Genet C Semin Med Genet.* Mar 5 2024:e32083. doi:10.1002/ajmg.c.32083
- 539 46. Davis SM, Teerlink C, Lynch JA, et al. Prevalence, Morbidity, and Mortality of
540 Men With Sex Chromosome Aneuploidy in the Million Veteran Program Cohort. *JAMA*
541 *Netw Open.* Mar 4 2024;7(3):e244113. doi:10.1001/jamanetworkopen.2024.4113
- 542 47. Berglund A, Stochholm K, Gravholt CH. The epidemiology of sex chromosome
543 abnormalities. *Am J Med Genet C Semin Med Genet.* Jun 2020;184(2):202-215.
544 doi:10.1002/ajmg.c.31805
- 545 48. Sood E, Newburger JW, Anixt JS, et al. Neurodevelopmental Outcomes for
546 Individuals With Congenital Heart Disease: Updates in Neuroprotection, Risk-
547 Stratification, Evaluation, and Management: A Scientific Statement From the American
548 Heart Association. *Circulation.* Mar 26 2024;149(13):e997-e1022.
549 doi:10.1161/cir.0000000000001211
- 550 49. Lipkin PH, Macias MM, COUNCIL ON CHILDREN WITH DISABILITIES SOD,
551 PEDIATRICS B. Promoting Optimal Development: Identifying Infants and Young
552 Children With Developmental Disorders Through Developmental Surveillance and
553 Screening. *Pediatrics.* 2020;145(1)doi:10.1542/peds.2019-3449
- 554 50. Roberts MY, Sone BJ, Jones MK, et al. What the Evidence Does (and Does Not)
555 Show for the Centers for Disease Control and Prevention Child Development
556 Milestones: An Illustrative Example Using Expressive Vocabulary. *J Speech Lang Hear*
557 *Res.* Sep 13 2023;66(9):3622-3632. doi:10.1044/2023_jslhr-23-00020
- 558 51. Association AS-L-H. ASHA statement on CDC's updated developmental
559 milestones. Accessed August 14, 2024, <https://www.asha.org/about/statements/ASHA-Statement-on-CDCDevelopmental-Milestones/>
- 560
561 52. Team TIS. No SLPs were in the room where it happened. The Informed SLP,
562 LLC. Accessed August 14, 2024, <https://www.theinformedslp.com/review/no-sl-ps-were-in-the-room-where-it-happened>
- 563
564 53. Limbos MM, Joyce DP. Comparison of the ASQ and PEDS in screening for
565 developmental delay in children presenting for primary care. *J Dev Behav Pediatr.* Sep
566 2011;32(7):499-511. doi:10.1097/DBP.0b013e31822552e9
- 567 54. Sices L, Stancin T, Kirchner L, Bauchner H. PEDS and ASQ developmental
568 screening tests may not identify the same children. *Pediatrics.* Oct 2009;124(4):e640-7.
569 doi:10.1542/peds.2008-2628
- 570 55. Sheldrick RC, Marakovitz S, Garfinkel D, Carter AS, Perrin EC. Comparative
571 Accuracy of Developmental Screening Questionnaires. *JAMA Pediatr.* Apr 1
572 2020;174(4):366-374. doi:10.1001/jamapediatrics.2019.6000
- 573 56. Voller SMB. Follow-Up Care for High-Risk Preterm Infants. *Pediatr Ann.* Apr 1
574 2018;47(4):e142-e146. doi:10.3928/19382359-20180325-03

- 575 57. Johnson S, Marlow N. Developmental screen or developmental testing? *Early*
576 *Hum Dev.* Mar 2006;82(3):173-83. doi:10.1016/j.earlhumdev.2006.01.008
- 577 58. Marks K, Hix-Small H, Clark K, Newman J. Lowering developmental screening
578 thresholds and raising quality improvement for preterm children. *Pediatrics.* Jun
579 2009;123(6):1516-23. doi:10.1542/peds.2008-2051
- 580 59. Gravholt CH, Ferlin A, Gromoll J, et al. New developments and future trajectories
581 in supernumerary sex chromosome abnormalities: a summary of the 2022 3rd
582 International Workshop on Klinefelter Syndrome, Trisomy X, and XYY. *Endocr Connect.*
583 Mar 1 2023;12(3)doi:10.1530/ec-22-0500
- 584 60. Andrioni F, Coman C, Ghita RC, Bularca MC, Motoi G, Fulger IV. Anxiety, Stress,
585 and Resilience Strategies in Parents of Children with Typical and Late Psychosocial
586 Development: Comparative Analysis. *Int J Environ Res Public Health.* Feb 14
587 2022;19(4)doi:10.3390/ijerph19042161
- 588 61. Scherr CL, Getachew-Smith HJ, Sudec L, Brooks JJ, Roberts M. Parents'
589 sensemaking processes in the identification of developmental delays and engagement
590 with early intervention services. *Soc Sci Med.* Jun 2020;255:112941.
591 doi:10.1016/j.socscimed.2020.112941
- 592 62. Leggett V, Jacobs P, Nation K, Scerif G, Bishop DV. Neurocognitive outcomes of
593 individuals with a sex chromosome trisomy: XXX, XYY, or XXY: a systematic review.
594 *Dev Med Child Neurol.* Feb 2010;52(2):119-29. doi:10.1111/j.1469-8749.2009.03545.x
- 595 63. Raznahan A, Lee NR, Greenstein D, et al. Globally Divergent but Locally
596 Convergent X- and Y-Chromosome Influences on Cortical Development. *Cereb Cortex.*
597 Jan 2016;26(1):70-9. doi:10.1093/cercor/bhu174
- 598 64. Urbanus E, Swaab H, Tartaglia N, Stumpel C, van Rijn S. Structural and
599 pragmatic language in young children with sex chromosome trisomy (XXX, XXY, XYY):
600 Predictive value for neurobehavioral problems one year later. *Clin Neuropsychol.* Apr
601 2023;37(3):650-675. doi:10.1080/13854046.2022.2067078
- 602 65. Green T, Flash S, Reiss AL. Sex differences in psychiatric disorders: what we can
603 learn from sex chromosome aneuploidies. *Neuropsychopharmacology.* Jan
604 2019;44(1):9-21. doi:10.1038/s41386-018-0153-2
- 605 66. Biesecker B. Genetic Counseling and the Central Tenets of Practice. *Cold Spring*
606 *Harb Perspect Med.* Mar 2 2020;10(3)doi:10.1101/cshperspect.a038968
- 607 67. Reimers R, High F, Kremen J, Wilkins-Haug L. Prenatal diagnosis of sex
608 chromosome aneuploidy-What do we tell the prospective parents? *Prenat Diagn.* Feb
609 2023;43(2):250-260. doi:10.1002/pd.6256
- 610 68. Matsubara K, Hattori T, Narumi S. Achievement of Developmental Milestones
611 Recorded in Real Time: A Mobile App-Based Study. *J Pediatr.* Jun 2022;245:201-
612 207.e9. doi:10.1016/j.jpeds.2022.02.018
- 613 69. Sheldrick RC, Schlichting LE, Berger B, et al. Establishing New Norms for
614 Developmental Milestones. *Pediatrics.* Dec 2019;144(6)doi:10.1542/peds.2019-0374
- 615 70. Cepanec M, Lice K, Simleša S. Mother-father differences in screening for
616 developmental delay in infants and toddlers. *J Commun Disord.* Jul-Aug
617 2012;45(4):255-62. doi:10.1016/j.jcomdis.2012.04.002
- 618 71. Majnemer A, Rosenblatt B. Reliability of parental recall of developmental
619 milestones. *Pediatric Neurology.* 1994/06/01/ 1994;10(4):304-308.
620 doi:[https://doi.org/10.1016/0887-8994\(94\)90126-0](https://doi.org/10.1016/0887-8994(94)90126-0)

- 621 72. Assessment of sex differences and heterogeneity in motor milestone attainment
622 among populations in the WHO Multicentre Growth Reference Study. *Acta Paediatr*
623 *Suppl.* Apr 2006;450:66-75. doi:10.1111/j.1651-2227.2006.tb02377.x
- 624 73. Sudry T, Amit G, Zimmerman DR, et al. Sex-Specific Developmental Scales for
625 Surveillance. *Pediatrics*. 2024;153(4)doi:10.1542/peds.2023-062483
- 626 74. Kelly Y, Sacker A, Schoon I, Nazroo J. Ethnic differences in achievement of
627 developmental milestones by 9 months of age: The Millennium Cohort Study. *Dev Med*
628 *Child Neurol*. Oct 2006;48(10):825-30. doi:10.1017/s0012162206001770
- 629 75. Lansdown RG, Goldstein H, Shah PM, et al. Culturally appropriate measures for
630 monitoring child development at family and community level: a WHO collaborative study.
631 *Bulletin of the World Health Organization*. 1996 1996;74(3):283-290.
- 632 76. Ozonoff S, Li D, Deprey L, Hanzel EP, Iosif AM. Reliability of parent recall of
633 symptom onset and timing in autism spectrum disorder. *Autism*. Oct 2018;22(7):891-
634 896. doi:10.1177/1362361317710798
- 635 77. Majnemer A, Rosenblatt B. Reliability of parental recall of developmental
636 milestones. *Pediatr Neurol*. Jun 1994;10(4):304-8. doi:10.1016/0887-8994(94)90126-0
- 637 78. Davis S, Howell S, Wilson R, et al. Advances in the Interdisciplinary Care of
638 Children with Klinefelter Syndrome. *Adv Pediatr*. Aug 2016;63(1):15-46.
639 doi:10.1016/j.yapd.2016.04.020
- 640 79. Wigby K, D'Epagnier C, Howell S, et al. Expanding the phenotype of Triple X
641 syndrome: A comparison of prenatal versus postnatal diagnosis. *Am J Med Genet A*.
642 Nov 2016;170(11):2870-2881. doi:10.1002/ajmg.a.37688
- 643 80. Tartaglia N, Howell S, Wilson R, et al. The eXtraordinary Kids Clinic: an
644 interdisciplinary model of care for children and adolescents with sex chromosome
645 aneuploidy. *J Multidiscip Healthc*. 2015;8:323-34. doi:10.2147/jmdh.S80242
646